Natural Phenomenon or Process – Page 4

Kyverna Therapeutics Cuts 16% of Staff in Q1 2025 Amid Pipeline Focus

4 months ago talkbio0Tagged Autoimmune Diseases, CAR-T, KYV-101, Kyverna, layoffs, pipeline development, Staff

Kyverna Therapeutics; layoffs; biotech; staff reduction; Q1 2025; CAR-T; autoimmune diseases; pipeline development; KYV-101

Fierce Biotech Layoff Tracker 2025: 10x Genomics cuts 8% of global workforce; NGM sheds 75% of staff

4 months ago talkbio0Tagged 2025, 75%, 8, Fierce, Generalized, Genomics, NGM, Staff

NGM, Genomics, Fierce, 8, Generalized, Staff, 75%, 2025

AI Drug Discovery Firm Insitro Lays Off 22% of Workforce Amid Ongoing Biotech Market Turmoil

4 months ago talkbio0Tagged Ambulatory Care Facilities, Aortic Valve Insufficiency, Artificial Intelligence, Biotech Layoffs, biotechnology layoffs, Drug Discovery, Industry, Insitro, Market, Readiness, restructuring, trends qualifier

Insitro, AI drug discovery, biotechnology layoffs, workforce reduction, tumultuous market, industry restructuring, biotech market trends, clinic readiness, cost-cutting, 2025 biotech layoffs

Marea Therapeutics Reports Positive Phase 2a Results for MAR001 in Lowering Remnant Cholesterol and Triglycerides

4 months ago4 months ago talkbio0Tagged Adverse event, ANGPTL4 gene, Antibodies, Dosage, Embryonic remnant, Hypertriglyceridemia, MAR001, MAR001[1, Phase 2a clinical trial, placebo-adjusted mean reduction, Positive

MAR001, Antibodies, ANGPTL4 gene, Embryonic remnant, Hypertriglyceridemia, Phase 2a clinical trial, Positive, placebo-adjusted mean reduction, Dosage, Adverse event, MAR001[1

CRISPR Therapeutics’ gene editing therapy reduces bad cholesterol and triglycerides by as much as 80%

4 months ago talkbio0Tagged cholesterol, Clinical Trials, Clustered Regularly Interspaced Short Palindromic Repeats, CTX310, Gene Modification, Genes, In Vivo, LDL Cholesterol Lipoproteins, Triglycerides

Gene Modification, Clustered Regularly Interspaced Short Palindromic Repeats, Triglycerides, LDL Cholesterol Lipoproteins, In Vivo, CTX310, Clinical Trials, cholesterol, Genes

NewAmsterdam’s pooled Phase 3 data; C4 seeks partners for solid tumor degrader

4 months ago talkbio0Tagged BROADWAY, Cardiovascular Diseases, LDL-C, NewAmsterdam, Obicetrapib, Pooled Sample

Pooled Sample, Obicetrapib, BROADWAY, NewAmsterdam, LDL-C, Cardiovascular Diseases

Mersana makes Emi-Le the one, laying off 55% of staff to narrow focus to B7-H4 ADC

4 months ago talkbio0Tagged 55%, Antibody-Drug Conjugates, Emi-Le, emiltatug ledadotin, Malignant neoplasm of breast, Mersana, VTCN1 gene

Emi-Le, Mersana, VTCN1 gene, Antibody-Drug Conjugates, emiltatug ledadotin, Malignant neoplasm of breast, 55%

Arvinas cuts workforce and pair of Pfizer-partnered cancer trials

4 months ago talkbio0Tagged Arvinas, Vepdegestrant

Arvinas, vepdegestrant

AstraZenecas Truqap Posts Another Pivotal Disappointment as Phase III Prostate Cancer Study Fails

4 months ago talkbio0Tagged ADT, androgen-deprivation therapy, AstraZeneca, CAPItello-280, capivasertib, Clinical Trials, Discontinuation (procedure), docetaxel, Failure (biologic function), Inhibitor, Metastatic castration-resistant prostate cancer, oncology setback, Phase 3 Clinical Trials, Progression-Free Survival, Proto-Oncogene Proteins c-akt, Radiographic, Survival, Truqap

Truqap, capivasertib, AstraZeneca, Phase III trial failure, CAPItello-280, metastatic castration-resistant prostate cancer (mCRPC), AKT inhibitor, docetaxel, androgen-deprivation therapy (ADT), oncology setback, clinical trial discontinuation, radiographic progression-free survival, overall survival

FDA Approves Johnson & Johnson’s Imaavy: A New Treatment Option for Generalized Myasthenia Gravis

4 months ago talkbio0Tagged Approved, Autoimmune Diseases, Blocker, FCGRT gene, FcRn, Imaavy, immunoglobulin G, Myasthenia Gravis, Generalized, nipocalimab-aahu, United States Food and Drug Administration

Imaavy, nipocalimab-aahu, FcRn blocker, generalized myasthenia gravis (gMG), FDA approval, Johnson & Johnson, autoimmune disease, IgG reduction